US Pharma MarketingThe post Inflammasome sets sights on Phase III amid eye disease drug’s mid-stage score appeared first on Clinical Trials Arena.
Inflammasome sets sights on Phase III amid eye disease drug’s mid-stage score
K8 slowed disease progression and trended towards improving visual acuity in GA, leading Inflammasome to draft Phase III plans for the drug. The post Inflammasome sets sights on Phase III amid eye disease drug’s mid-stage score appeared first on Clinical Trials Arena .
K8 slowed disease progression and trended towards improving visual acuity in GA, leading Inflammasome to draft Phase III plans for the drug.
Source: Clinical Trials Arena